X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (771) 771
humans (636) 636
male (612) 612
prostatic neoplasms - drug therapy (317) 317
aged (270) 270
tosyl compounds (261) 261
middle aged (259) 259
anilides - administration & dosage (243) 243
nitriles (230) 230
tosyl compounds - therapeutic use (225) 225
animals (224) 224
tosyl compounds - administration & dosage (223) 223
prostate cancer (222) 222
anilides - therapeutic use (186) 186
androgen antagonists - therapeutic use (167) 167
urology & nephrology (164) 164
prostatic neoplasms - pathology (158) 158
bicalutamide (153) 153
female (153) 153
androgen antagonists - administration & dosage (148) 148
adult (145) 145
tosyl compounds - pharmacology (145) 145
nitriles - administration & dosage (135) 135
oncology (135) 135
treatment outcome (126) 126
aged, 80 and over (119) 119
abridged index medicus (118) 118
anilides - pharmacology (115) 115
asthma - drug therapy (106) 106
prostate-specific antigen - blood (106) 106
rats (106) 106
pharmacology & pharmacy (103) 103
tosyl compounds - adverse effects (102) 102
cancer (90) 90
antineoplastic combined chemotherapy protocols - therapeutic use (89) 89
anilides - adverse effects (88) 88
androgen antagonists - pharmacology (86) 86
antineoplastic agents, hormonal - therapeutic use (86) 86
carcinoma (85) 85
nitriles - therapeutic use (83) 83
time factors (83) 83
prostatic neoplasms - blood (80) 80
care and treatment (79) 79
double-blind method (74) 74
administration, oral (70) 70
goserelin - administration & dosage (70) 70
asthma (69) 69
leukotriene antagonists - therapeutic use (69) 69
mice (69) 69
androgen antagonists - adverse effects (68) 68
nitriles - pharmacology (68) 68
antineoplastic agents, hormonal - administration & dosage (67) 67
dose-response relationship, drug (67) 67
flutamide (67) 67
zafirlukast (67) 67
follow-up studies (63) 63
therapy (63) 63
antineoplastic agents - therapeutic use (62) 62
anti-asthmatic agents - therapeutic use (61) 61
antineoplastic agents - administration & dosage (61) 61
prostatic neoplasms - surgery (60) 60
prostatic neoplasms - metabolism (57) 57
adolescent (56) 56
orchiectomy (56) 56
cell line, tumor (55) 55
adenocarcinoma - drug therapy (54) 54
nitriles - adverse effects (54) 54
prostatectomy (54) 54
drug administration schedule (53) 53
androgens (52) 52
castration (52) 52
quality of life (52) 52
receptors, androgen - metabolism (51) 51
leuprolide - administration & dosage (50) 50
neoplasm staging (50) 50
prostatic neoplasms - mortality (50) 50
research (50) 50
endocrinology & metabolism (48) 48
radical prostatectomy (48) 48
monotherapy (46) 46
administration, inhalation (45) 45
prostate (45) 45
casodex (44) 44
drug therapy (44) 44
radiotherapy (44) 44
combined modality therapy (40) 40
analysis (39) 39
androgen receptor (38) 38
child (38) 38
leukotriene antagonists - administration & dosage (38) 38
prostatic neoplasms - therapy (38) 38
drug therapy, combination (37) 37
expression (37) 37
immunology (37) 37
testosterone - blood (37) 37
disease progression (36) 36
flutamide - administration & dosage (36) 36
flutamide - therapeutic use (36) 36
men (36) 36
prospective studies (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (747) 747
Japanese (16) 16
Spanish (9) 9
Russian (7) 7
German (6) 6
French (5) 5
Chinese (3) 3
Italian (3) 3
Norwegian (2) 2
Polish (2) 2
Bulgarian (1) 1
Czech (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 10/2013, Volume 19, Issue 19, pp. 5505 - 5512
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2013, Volume 368, Issue 14, pp. 1314 - 1325
Despite theoretical benefits of intermittent as compared with continuous androgen-deprivation therapy in patients with metastatic prostate cancer, intermittent... 
MEDICINE, GENERAL & INTERNAL | THERAPY | CLINICAL-TRIAL | FLUTAMIDE | QUALITY-OF-LIFE | SUPPRESSION | CARCINOMA | LEUPROLIDE | Confidence Intervals | Follow-Up Studies | Anilides - adverse effects | Humans | Middle Aged | Male | Gonadotropin-Releasing Hormone - analogs & derivatives | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis - drug therapy | Penile Erection - drug effects | Gonadotropin-Releasing Hormone - therapeutic use | Goserelin - adverse effects | Prostatic Neoplasms - drug therapy | Goserelin - administration & dosage | Prostatic Neoplasms - pathology | Tosyl Compounds - administration & dosage | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Tosyl Compounds - adverse effects | Anilides - administration & dosage | Survival Analysis | Quality of Life | Aged | Androgen Antagonists - administration & dosage | Nitriles - adverse effects | Usage | Care and treatment | Patient outcomes | Androgen suppression therapy | Drug therapy | Prostate cancer | Methods | Cancer | Statistical analysis | Mental disorders | Prostate-specific antigen | Clinical trials | Patients | Survival | Quality of life | Metastases | Androgens | Castration | Stem cells | Luteinizing hormone | Prostate | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 320 - 327
Journal Article
Oncogene, ISSN 0950-9232, 07/2015, Volume 34, Issue 28, pp. 3700 - 3710
Androgen receptor splicing variants (ARVs) that lack the ligand-binding domain (LBD) are associated with the development of castration-resistant prostate... 
ACTIVATION | SOLID TUMORS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHROMOGRANIN-A | MECHANISMS | ANTITUMOR-ACTIVITY | SPLICE VARIANTS | CELL BIOLOGY | LYMPH-NODE METASTASES | NUCLEAR-LOCALIZATION | ONCOLOGY | GENETICS & HEREDITY | TRAIL-INDUCED APOPTOSIS | PROGRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nitriles - pharmacology | Humans | Pyrazines - administration & dosage | Receptors, Androgen - metabolism | Male | NF-kappa B - metabolism | Antineoplastic Agents - administration & dosage | Prostatic Neoplasms, Castration-Resistant - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Tosyl Compounds - pharmacology | Nitriles - administration & dosage | Antineoplastic Agents - pharmacology | Boronic Acids - administration & dosage | NF-kappa B - antagonists & inhibitors | Bortezomib | Tosyl Compounds - administration & dosage | Androgen Antagonists - pharmacology | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Xenograft Model Antitumor Assays | Receptors, Androgen - genetics | Anilides - administration & dosage | Signal Transduction - drug effects | Anilides - pharmacology | Cell Line, Tumor | Androgen Antagonists - administration & dosage | Pyrazines - pharmacology | Boronic Acids - pharmacology | Androgens | Drug therapy | Gene expression | Neurons | Prostate cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2015, Volume 33, Issue 4, pp. 332 - 339
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2005, Volume 352, Issue 15, pp. 1519 - 1528
Journal Article
Journal Article
Oncogene, ISSN 0950-9232, 11/2017, Volume 36, Issue 46, pp. 6359 - 6373
The antiandrogen bicalutamide is widely used in the treatment of advanced prostate cancer (PCa) in many countries, but its effect on castration-resistant PCa... 
MAMMALIAN TARGET | RAPAMYCIN | SURVIVAL | ACTIVATION | PROTEIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | INITIATION-FACTOR 4E | CELL-PROLIFERATION | TRANSLATION | CELL BIOLOGY | ONCOLOGY | GROWTH | GENETICS & HEREDITY | PROGRESSION | TOR Serine-Threonine Kinases - metabolism | Humans | Receptors, Androgen - metabolism | Eukaryotic Initiation Factor-4E - metabolism | Male | Everolimus - administration & dosage | Intracellular Signaling Peptides and Proteins - metabolism | Purines - administration & dosage | Nitriles - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Phosphorylation - drug effects | Aniline Compounds - administration & dosage | Protein-Serine-Threonine Kinases - metabolism | Tosyl Compounds - administration & dosage | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Serine - metabolism | Blotting, Western | Xenograft Model Antitumor Assays | Sirolimus - administration & dosage | Animals | Anilides - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Care and treatment | Androgens | Phosphorylation | Usage | Androgen suppression therapy | Rapamycin | Dosage and administration | Research | Diagnosis | Protein kinases | Prostate cancer | TOR protein | Cell proliferation | Translation | Animal models | Transcription | Threonine | Clinical trials | Extracellular signal-regulated kinase | MAP kinase | Antagonists | siRNA | Survivin | Kinases | Castration | Protein kinase | Cell lines | Xenografts | Antiandrogens | Initiation factor eIF-4E | Prostate | Index Medicus | mTOR | eIF4E | androgen receptor | Mnk | castration resistant prostate cancer
Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2017, Volume 23, Issue 8, pp. 1974 - 1980
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 3, pp. 229 - 237
Purpose Ligand-mediated activation of the androgen receptor (AR) is critical for prostate cancer (PCa) survival and proliferation. The failure to completely... 
THERAPY | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | TESTOSTERONE | ADENOCARCINOMA | GROWTH | RECEPTOR | RADICAL PROSTATECTOMY | CASTRATION | SPLICE VARIANTS | DIHYDROTESTOSTERONE | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Androgen Receptor Antagonists - therapeutic use | Ketoconazole - administration & dosage | Humans | Middle Aged | Receptors, Androgen - metabolism | Male | Prostate - metabolism | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - therapeutic use | Dihydrotestosterone - blood | Aged, 80 and over | Androsterone - blood | Biomarkers, Tumor - metabolism | Prostatic Neoplasms - blood | Chemotherapy, Adjuvant | Testosterone - blood | Molecular Targeted Therapy - methods | Prostatic Neoplasms - drug therapy | Dihydrotestosterone - metabolism | Goserelin - administration & dosage | Prostatic Neoplasms - pathology | Tosyl Compounds - administration & dosage | Treatment Outcome | Prostate-Specific Antigen - blood | Pilot Projects | Azasteroids - administration & dosage | Receptors, Androgen - genetics | Anilides - administration & dosage | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - methods | 5-alpha Reductase Inhibitors - administration & dosage | Androgen Antagonists - therapeutic use | Dutasteride | Aged | Neoplasm Staging | Index Medicus | ORIGINAL REPORTS | To16
Journal Article